Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC125810.15690/vramn1258ENDOCRINOLOGY: CURRENT ISSUESАКТУАЛЬНЫЕ ВОПРОСЫ ЭНДОКРИНОЛОГИИResearch ArticleGastric neuroendocrine neoplasias: literature reviewНейроэндокринные неоплазии желудка: обзор литературы67014723962086-7513MikhalevaLiudmila M.МихалеваЛюдмила Михайловна
Russian Federation

MD, PhD, Professor

д.м.н., профессор

mikhalevalm@yandex.ru571955141122242-0958VasyukovaOlesya A.ВасюковаОлеся Александровна
Russian Federation

Junior Researcher, Laboratory of Clincal Morphology, Research Institute of Human Morphology; pathologist in the

младший научный сотрудник лаборатории клинической морфологии ФГБНУ НИИ морфологии человека; врач-патологоанатом патологоанатомического отделения

o.vas.93@gmail.comBirukovAndrey E.БирюковАндрей Евгеньевич
Russian Federation

MD, PhD

к.м.н.

bervost@rambler.ruhttps://orcid.org/0000-0002-1426-968X6891-6636MidiberKonstantin Yu.МидиберКонстантин Юрьевич
Russian Federation
midiberkonst@gmail.comhttps://orcid.org/0000-0002-1826-9169AkopyanEmma P.АкопянЭмма Петросовна
Russian Federation
vanilsheep@yandex.ruhttps://orcid.org/0000-0002-5646-26053157-3880KhovanskayaTatyana N.ХованскаяТатьяна Николаевна
Russian Federation
zimavnebe@mail.ruhttps://orcid.org/0000-0002-1041-85618401-8694GuschinMikhail Yu.ГущинМихаил Юрьевич
Russian Federation

MD, PhD

к.м.н.

guschin.michail@yandex.ruResearch Institute of Human MorphologyНаучно-исследовательский институт морфологии человекаCity Clinical Hospital No. 31 of the Moscow City Health DepartmentГородская клиническая больница № 31 Департамента здравоохранения города Москвы12032020180620207521691771412201925022020Copyright ©; 2020, "Paediatrician" Publishers LLCCopyright ©; 2020, Издательство "Педиатръ"2020"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/article/view/1258

Introduction: The gastric neuroendocrine neoplasias (NEN) are being diagnosed more and more often due to the wide spread of endoscopy methods and an increase in the imaging range, despite the rarity of the gastric neuroendocrine tumors (NETs) (which amounts to about 9% of all gastrointestinal neuroendocrine tumors and 0.3% of all gastric tumors). It is extremely important to distinguish in which case clinician and pathologist should suspect a neuroendocrine tumor and to classify it correctly, both at the stage of esophagogastroduodenoscopy and during pathological examination, because all these components affect the choice of the surgery extent, subsequent drug therapy, as well as the possibility of more accurate metastasis prognosis and the patient outcome.

Aim: The aim of this literature review is to systematize, generalize and discuss the recent data on gastric neuroendocrine tumors with a focus on current classifications including their critical analysis, and to show promising ways in the endoscopic and morphological diagnostics of these tumors, which, in turn, will have an effect on patient management. The search was performed among articles in the PubMed database (in English and German) and among Russian articles published on the eLibrary and Cyberleninka platforms using the following keywords: gastric neuroendocrine tumor, gastric carcinoid, gastric NET pathology, gastric NET morphology, gastric NET morphology, gastric NET diagnostics. The papers on surgical treatment methods, adjuvant therapy, as well as drug therapy with somatostatin analogues and other drugs were excluded. A brief retrospective journey into the history of neouroendocrine neoplasias serves to remind the histology and distribution of neuroendocrine cells in the gastric mucosa, followed by chronological review of NEN discovery and theory development up to the present moment. The morphological classification of gastric NET consisting of 4 possible types is highlighted: the correct interpretation of the pathological findings, taking into account not only the histological features of the tumor itself, but also of the adjacent mucosa, allows to suggest the appropriate managment, which fundamentally affects patient survival. The review provides other current classifications of the gastric neuroendocrine neoplasia depending on its location, embryogenesis, functional activity, histological grade (with a focus on the Ki-67 labeling index counting, and ways to improve the interobserver reliability in routine practice). Moreover, the differences in the gastric NET and NEC TNM classification are emphasized. The drawbacks of all classifications are discussed and the possibilities for their further development are considered. An important part of the review is the description of a possible immunohistochemical markers, since immunohistochemistry is widely used to confirm the diagnosis. In addition, INSM1 (insulinomaassociatedprotein 1), the new immunohistochemical and molecular marker for NEN is discussed: according to the literature, it contributes to more accurate assessment of the tumor malignant potential and the metastatic risk. Furthermore, modern methods of endoscopic and PET/CT imaging (68-gallium DOTATATE PET/CT, molecular imaging using SSTR (somatostatin receptor) PET/CT or GLP-1R (Glucagon-like peptide-1 receptor) SPECT (single photon emission computed tomography)/CT), which allows the clinician to suspect a NEN even before morphological analysis of the resected specimen and adequately select the extent of surgical intervention are shown.

Conclusion: We would like to reiterate the importance of further research on the gastric NET subtype pathogenesis and their clinical behavior, also of the correlation of the endoscopic, morphological, and immunohistochemical picture with the patient prognosis to improve managment tactics.

Актуальность. Несмотря на редкость возникновения нейроэндокринных неоплазий желудка (около 9% всех нейроэндокринных опухолей желудочно-кишечного тракта и 0,3% всех опухолей желудка), диагноз ставится все чаще благодаря широкому распространению эндоскопических методов исследований и распространению различных способов визуализации.

Целью настоящей работы является систематизация, обобщение и обсуждение накопленных за последние годы данных о нейроэндокринных опухолях желудка. Проведен поиск специализированной литературы в базах данных PubMed (на английском и немецком языках), eLibrary и Cyberleninka по ключевым слова «нейроэндокринные опухоли желудка» (gastric neuroendocrine tumor), «карциноид желудка» (gastric carcinoid), «патологическая анатомия нейроэндокринных опухолей желудка» (gastric neuroendocrine tumor pathology), «морфология нейроэндокринных опухолей желудка» (gastric neuroendocrine tumor morphology), «диагностика нейроэндокринных опухолей желудка» (gastric neuroendocrine tumor diagnostics). Из обзора были исключены статьи, предметом которых являлись хирургические методики лечения, адъювантная терапия, а также лекарственная терапия аналогами соматостатина и другими препаратами. Приведены действующие классификации нейроэндокринных неоплазий желудка, в том числе морфологическая классификации нейроэндокринных опухолей желудка по 4 возможным типам, а также разделение в зависимости от локализации, эмбриогенеза, функциональной активности, степени дифференцировки (сравнение классификаций Всемирной организации здравоохранения 2010 и новейшего издания 2019 г.); подчеркнуты различия с классификацией стадий злокачественных новообразований для нейроэндокринных опухолей и нейроэндокринной карциномы желудка; обсуждаются недостатки этих классификаций и перспективы их дальнейшего развития.

Заключение. Понимание, в каких случаях следует заподозрить наличие именно нейроэндокринной нэоплазии, и как правильно классифицировать выявленное по результатам эзофагогастродуоденоскопии и морфологического исследования новообразование имеет чрезвычайную важность, поскольку все эти компоненты оказывают влияние на выбор объема хирургического вмешательства, последующую медикаментозную терапию, а также на возможность более точного прогнозирования метастатического распространения опухоли и исход заболевания.

gastric neuroendocrine neoplasianeuroendocrine carcinomamixed neuroendocrine-non-neuroendocrine neoplasmsimmunohistochemistry methodsgastrointestinal endoscopy methodsнейроэндокринные неоплазии желудканейроэндокринная карциномаMiNENиммуногистохимические методыэндоскопическая диагностика в гастроэнтерологииНаучно-исследовательский институт морфологии человекаResearch Institute of Human MorphologyАААА-А19-119021590053-6Solcia E, Capella C, Vassallo G, Buffa R. Endocrine cells of the gastric mucosa. Int Rev Cytol. 1975;42:223–286. doi: 10.1016/s0074-7696(08)60982-1.Кит О.И., Дерижанова И.С., Карнаухов Н.С. Вопросы классификации нейроэндокринных опухолей желудка // Вопросы онкологии. ― 2016. ― Т.62. ― №5. ― С. 573−579. [Kit OI, Derizhanova IS, Karnaukhov NS. Issues on classification of gastric neuroendocrine tumors. Problems in oncology. 2016;62(5):573−579. (In Russ).]Oberndorfer S. Karzinoide tumoren des dünndarms. Frankf Z Pathol. 1907;1:425–432. (In German).Klöppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol. 2007;18(3):141–144. doi: 10.1007/s12022-007-0021-9.Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994−1006. doi: 10.1016/0016-5085(93)90266-f.Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–560. doi: 10.1007/bf00199342.Moreira RK, Washington K. Pathology of gastrointestinal neuroendocrine tumors: an update. Surg Pathol Clin. 2010;3(2):327–347. doi: 10.1016/j.path.2010.05.003.Cockburn AN, Morgan CJ, Genta RM. Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist. Adv Anat Pathol. 2013;20(3):148−157. doi: 10.1097/PAP.0b013e31828d185d.Shi C, Adsay V, Bergsland EK, et al. CAP protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. Includes pTNM requirements from the 8th Edition, AJCC Staging Manual; 2017. Avalaible from: https://documents.cap.org/protocols/cp-stomach-net-17protocol-4001.pdf.Daskalakis K, Tsoli M, Karapanagioti A, et al. Recurrence and metastatic potential in type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2019;91(4):534−543. doi: 10.1111/cen.14055.Abraham SC, Aidan Carney J, Ooi A, et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–975. doi: 10.1097/01.pas.0000163363.86099.9f.Ooi A, Ota M, Katsuda S, et al. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol. 1995;6(3):229–237. doi: 10.1007/bf02739887.Waldum HL, Hauso Ø, Brenna E, et al. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? Scand J Gastroenterol. 2016;51(7):767–773. doi: 10.3109/00365521.2016.1143527.La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol. 2016;27(4):284–311. doi: 10.1007/s12022-016-9432-9.Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–124. doi: 10.1159/000443168.Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Cur Gastroenterol Rep. 2019;21(4):13. doi: 10.1007/s11894-019-0684-7.Gastric neuroendocrine neoplasms. In: WHO Classification of tumours. Digestive system tumours. 5th ed. Lyon: IARC; 2019. Рр. 104−109.Kim BS, Park YS, Yook JH, Kim BS. Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma. Therap Adv Gastroenterol. 2017;10(5):407−415. doi: 10.1177/1756283X17697870.Клинические рекомендации «Нейроэндокринные опухоли». ― М., 2017. [Klinicheskie rekomendatsii “Neiroendokrinnye opukholi”. Moscow; 2017. (In Russ).] Доступно по: https://oncology-association.ru/files/clinical-guidelines_adults/neiroendokrinnye_opukholi.pdf. Ссылка активна на 12.11.2019.Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186−194. doi: 10.1159/000443172.Делекторская В.В., Кушлинский Н.Е. Нейроэндокринные опухоли пищеварительной системы: морфологический спектр и клеточная пролиферация (индекс Ki-67) // Вестник РАМН. ― 2013. ― Т.68. ― №5. ― С. 28–37. [Delektorskaya VV, Kushliskiy NE. Neuroendocrine tumors of digestive system: morphologic spectrum and cell proliferation (КІ67 index). Annals of the Russian Academy of Medical Sciences. 2013;68(5):28–37. (In Russ).] doi: 10.15690/vramn.v68i5.660.Grillo F, Albertelli M, Brisigotti MP, et al. Grade increases in gastro-enteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 2016;103(5):452−459. doi: 10.1159/000439434.Solcia E, Arnold R, Capella C, et al. Tumours of the stomach: neuroendocrine neoplasms of the stomach. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO Classification of tumours of the digestive system. 2nd ed. Lyon: IARC; 2010. Рр. 64–68.Tang LH, Untch BR, Reidy DL, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22(4):1011–1017. doi: 10.1158/1078-0432.CCR-15-0548.Milione M, Maisonneuve P, Spada F, et al. The clinicopathologic heterogeneity of Grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85−93. doi: 10.1159/000445165.Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO Classification of tumours of the digestive system. Histopathology. 2020;76(2):182−188. doi: 10.1111/his.13975.Amin MB, Edge SB, Greene FL, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “Personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93−99. doi: 10.3322/caac.21388.Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev. 2016;50:61−67. doi: 10.1016/j.ctrv.2016.08.006.Milione M, Fazio N. G3 GEP NENs category: are basic and clinical investigations well integrated? Endocrine. 2018;60(1):28−30. doi: 10.1007/s12020-017-1365-7.Rosenbaum JN, Guo Z, Baus RM, et al. INSM1 a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol. 2015;144(4):579−591. doi: 10.1309/AJCPGZWXXBSNL4VD.Tsukamoto H, Mizoshita T, Sasaki M, et al. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach. Asian Pac J Cancer Prev. 2011;12(4):1049–1054.Cao L, Mizoshita T, Tsukamoto T, et al. Development of carcinoid tumors of the glandular stomach and effects of eradication in Helicobacter pylori-infected Mongolian gerbils. Asian Pac J Cancer Prev. 2008;9(1):25–30.Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-Dotatate PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708−714. doi: 10.2967/jnumed.115.163865.Cavallaro A, Zanghì A, Cavallaro M, et al. The role of 68-Ga-Dotatoc CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg. 2014;12(Suppl 1):225–231. doi: 10.1016/j.ijsu.2014.05.017.Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471−487. doi: 10.3322/caac.21493.Schraml C, Schwenzer NF, Sperling O, et al. Staging of neuroendocrine tumours: comparison of [(6)(8)Ga]Dotatoc multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13(1):63−72. doi: 10.1102/1470-7330.2013.0007.Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56(4):613−615. doi: 10.2967/jnumed.114.153189.Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) ― imaging and staging. Best Pract Res Clin Endocrinol Metab. 2016;30(1):45−57. doi: 10.1016/j.beem.2016.01.003.Патент РФ на изобретение RU № 2613300. Кит О.И., Дерижанова И.С., Карнаухов Н.С. Cпособ диагностики низкодифференцированного нейроэндокринного рака желудка. [Patent RUS № 2613300. Kit OI, Derizhanova IS, Karnaukhov NS. Sposob diagnostiki nizkodifferentsirovannogo neiroendokrinnogo raka zheludka. (In Russ).] Доступно по: https://yandex.ru/patents/doc/RU2613300C1_20170315. Ссылка активна на 12.11.2019.Kloeppel G. [Neuroendocrine neoplasms: two families with distinct features unified in one classification. (In German)]. Pathologe. 2019;40(3):211–219. doi: 10.1007/s00292-019-0594-3.